Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
- 19 September 2011
- journal article
- Published by Elsevier BV in Journal of Clinical Virology
- Vol. 52 (4), 321-327
- https://doi.org/10.1016/j.jcv.2011.08.015
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Characterization of V36C, a Novel Amino Acid Substitution Conferring Hepatitis C Virus (HCV) Resistance to Telaprevir, a Potent Peptidomimetic Inhibitor of HCV ProteaseAntimicrobial Agents and Chemotherapy, 2010
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Identification of HCV protease inhibitor resistance mutations by selection pressure-based methodNucleic Acids Research, 2009
- Temporal Dynamics of a Predominant Protease Inhibitor–Resistance Mutation in a Treatment-Naive, Hepatitis C Virus–Infected IndividualThe Journal of Infectious Diseases, 2009
- Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)Antimicrobial Agents and Chemotherapy, 2009
- Expert opinion on the treatment of patients with chronic hepatitis CJournal of Viral Hepatitis, 2009
- Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapyHepatology, 2008
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsHepatology, 2008
- Immunology of hepatitis B virus and hepatitis C virus infectionNature Reviews Immunology, 2005